The AHSN Network is a key member of the AAC, the umbrella body across the UK health innovation ecosystem, providing more joined up support for innovators and setting the strategy for innovation in the health system. Find out more.

The AAC supports innovation at all stages across the development pipeline: from research and horizon scanning for innovations that address the population’s needs, to support for adoption and spread of proven innovations.

Download the AAC flyer to find out more.

Rapid Uptake Products

The government is providing £2 million to give more patients access to proven innovations through the Accelerated Access Collaborative (AAC).

Seven innovative technology areas were identified by the AAC that improve patients’ lives but are not currently available to everyone who could benefit. This first batch of ‘rapid uptake’ products was selected by leaders in the health and care system, and includes a range of treatments for conditions such as cancer, heart disease and multiple sclerosis.

Supporting the ‘rapid uptake’ products will not only help 500,000 patients to access new treatments, they will also provide cost savings to the NHS of £30 million, while helping to reinforce the UK’s position as a global leader in health innovation.

The products will be spread through the AHSN Network’s Innovation Exchange, which matches solutions to the needs of their local health and care systems.

The rapid uptake products are:

  • Heartflow – A non-invasive personalized cardiac test that reduces the need for unnecessary procedures
  • Placental growth factor (PIG-F) based testing for suspected pre-eclampsia – tests for early diagnosis of pre-eclampsia in pregnant women, which if unmonitored, can cause serious complications for mother and baby.
  • PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia – cost-effective drugs that significantly lower cholesterol.
  • High sensitivity troponin tests for early rule out of myocardial infarction (acute) – diagnostic tests that detect whether or not a patient is at risk or previously had a heart attack.
  • Quantitative faecal immunochemical tests for colorectal cancer – diagnostic tests that reduce referrals for patients with suspected colorectal cancer.
  • Cladribine (brand name: Mavenclad) for treating highly active relapsing-remitting multiple sclerosis in adults – a drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden
  • Urolift for lower urinary tract symptoms of benign prostatic hyperplasia.

First phase of the Accelerated Access Collaborative Pathway Transformation Fund (PTF) launched

Funding through the new PTF will be made available to help NHS organisations integrate the rapid uptake products into everyday practices, supporting an improvement in equality of access and reducing health inequalities that exist regarding diagnosis and disease management.

The PTF can help providers overcome more practical obstacles to deploying these products, such as: training staff on how to use new equipment; pathway redesign and/or business support expertise; providing specialist nurses/clinical staff needed to implement a new part of the procedure; or covering double running costs.

Phase One

This is the first phase of AAC Pathway Transformation Fund, focusing on four of the AAC rapid uptake products (UroLift, placental growth factor-based testing, Hearflow and high-sensitivity troponin testing in an under three-hour protocol), with a closing date of midnight on 16 August.  We strongly encourage any Providers wishing to adopt any of these four rapid uptake products to apply.

Read more here.